Table 2 Patient-specific iPSC models of hematological disorders
From: Differentiation of human induced pluripotent stem cells into erythroid cells
Authors | Disorder | iPSC cell source | Ref. |
|---|---|---|---|
Ye et al. 2009 | Myeloproliferative disorders (MPDs) | iPSCs from peripheral blood CD34+ cells of patients with MPDs | [95] |
Zou et al. 2011 | Chronic granulomatous disease (CGD) | iPSCs from patient with X-linked CGD | [96] |
Kumano et al. 2012 | Chronic myelogenous leukemia (CML) | iPSCs from imatinib-sensitive CML patient | [97] |
Chang et al. 2012 | α-Thalassemia (α-Thal) | iPSCs from α-Thal fibroblasts | [98] |
Garçon et al. 2013 | Diamond Blackfan anemia (DBA) | iPSCs from fibroblasts of DBA patient | [99] |
Bedel et al. 2013 | CML | iPSCs from CD34+ blood cells isolated from CML patients | [100] |
Yuan et al. 2013 | Paroxysmal nocturnal hemoglobinuria (PNH) | iPSCs from adult male dermal fibroblasts | [101] |
Saliba et al. 2013 | Polycythemia vera (PV) | iPSCs from 2 polycythemia vera patients carrying a heterozygous and a homozygous mutated JAK2 JAK2V617F | [102] |
Sakurai et al. 2014 | Familial platelet disorder (FPD)/AML | iPSCs from three distinct FPD/AML pedigrees | [103] |
Sun et al. 2014 | Sickle cell disease (SCD) | iPSCs from patient with SCD mutation | [104] |
Ye et al. 2014 | PV | iPSCs from PV patient blood | [105] |
Xie et al. 2014 | β-Thalassemia (β-Thal) | iPSCs from patient with β-Thal | [106] |
Amabile et al. 2015 | CML | Primary bone marrow cells obtained from a BCR-ABL-positive CML patient | [107] |
Ge et al. 2015 | DBA | iPSCs from DBA patients carrying RPS19 or RPL5 mutations | [108] |
Park et al. 2015 | Hemophilia A (HA) | iPSCs from patients with chromosomal inversions that involve introns 1 and 22 of the F8 gene | [109] |
Kotini et al. 2015 | Myelodysplastic syndromes (MDS) | iPSCs from hematopoietic cells of MDS patients | [110] |
Huang et al. 2015 | SCD | iPSCs from adult patients of SCD, which harbor the homozygous βs mutation in the HBB gene | [111] |
Chang et al. 2015 | Severe combined immunodeficiency (SCID) | iPSCs from SCID patients with Janus family kinase (JAK3)-deficient cells | [112] |
Menon et al. 2015 | X-linked severe SCID (SCID-X1) | iPSCs from SCID-X1 patients | [113] |
Ingrungruanglert et al. 2015 | Wiskott-Aldrich syndrome (WAS) | iPSCs from patients with mutations in WASP | [114] |
Wu et al. 2016 | HA | iPSCs from peripheral blood from severe HA patients | [115] |
Pang et al. 2016 | HA | iPSCs from patients with severe HA | [116] |
Niu et al. 2016 | β-Thal | iPSCs from patient with β-Thal | [117] |
Laskowski et al. 2016 | WAS | iPSCs from CD34+ hematopoietic progenitor cells of a WAS patient | [118] |
Doulatov et al. 2017 | DBA | iPSCs from skin fibroblasts from DBA patient | [119] |
He et al. 2017 | Hemophilia B (HB) | iPSCs from HB patient | [120] |
Chao et al. 2017 | Acute myeloid leukemia (AML) | iPSCs from AML patient | [121] |
Kotini et al. 2017 | AML | iPSC from patients with low-risk MDS (refractory anemia [RA]), high-risk MDS (RA with excess blasts [RAEB]) and secondary AML (sAML or MDS/AML from preexisting MDS) | [122] |
Miyauchi et al. 2018 | CML | iPSCs from the bone marrow of two CML-CP patients | [123] |
Olgasi et al. 2018 | HA | iPSCs from peripheral blood (PB) CD34+ cells of HA patient | [124] |
Ramaswamy et al. 2018 | HB | iPSCs from HB patients | [125] |
Lyu et al. 2018 | HB | iPSC from peripheral blood mononuclear cells (PBMNCs) | [126] |
Cai et al. 2018 | β-Thal | iPSCs from patient with β-Thal | [127] |
Wattanapanitch et al. 2018 | HbE/β-Thal | iPSCs from Skin cells of HbE/β-Thal patients | [128] |
Sfougataki et al. 2019 | β-Thal, SCD, DBA, severe aplastic anemia (SAA), dedicator of cytokinesis 8 (DOCK8) immunodeficiency | iPSCs from human bone marrow-derived mesenchymal stromal cells (BM-MSCs) | [129] |
Kohara et al. 2019 | Type IV congenital dyserythropoietic anemia (CDA) | iPSCs from CDA patient carrying the KLF1 E325K mutation | [130] |
Hoffmann et al. 2020 | Severe congenital neutropenia (SCN) | iPSCs from a SCN patient with a nonsense mutation in the glucose-6-phosphatase catalytic subunit 3 (G6PC3) gene | [131] |